IMR Press / FBL / Volume 11 / Issue 2 / DOI: 10.2741/1906

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer
Show Less
1 Clinical Trials Unit, National Cancer Institute, Naples, Italy
2 Division of Medical Oncology B, National Cancer Institute, Napoli, Italy
3 Division of Ginecology, National Cancer Institute, Napoli, Italy

Academic Editor: Antonio Giordano

Front. Biosci. (Landmark Ed) 2006, 11(2), 1585–1590; https://doi.org/10.2741/1906
Published: 1 May 2006
(This article belongs to the Special Issue Gene targets for modulating cell growth)
Abstract

Anemia significantly affects quality of life of cancer patients, but the impact of hemoglobin levels on survival is still unclear. The aim of this retrospective study was to assess the prognostic role of pre-chemotherapy hemoglobin levels in patients with ovarian cancer. Two hundred twenty-two patients were divided in 3 groups based on baseline hemoglobin levels (< 10 gr/dl (54 pts., 24%); 10-11.9 gr/dl (87 pts., 39%), ≥ 12 gr/dl (82 pts., 37%)). Correlations among baseline characteristics (age, ECOG performance status, stage, grading, histology, residual disease after primary surgery) and baseline hemoglobin level were analyzed. Poor performance status (p = 0.03), more advanced stage (p = 0.01), and sub-optimal residual disease (p = 0.002) were more frequent in patients with lower hemoglobin values. There was no significant correlation between baseline hemoglobin level and response rate to subsequent chemotherapy. Based on univariate analysis, hemoglobin categories were statistically significant predictors for time to progression (p = 0.0002) and overall survival (p < 0.0001). Based on multivariate analysis, patients with hemoglobin between 10 and 12 g/dl had a 1.45 hazard ratio (HR) for recurrence and a 1.35 HR of death compared with patients with normal hemoglobin. Patients with hemoglobin < 10 g/dl had a 2.02 HR of recurrence and a 2.49 HR of death compared with patients with normal hemoglobin. These findings show that hemoglobin level prior to chemotherapy is an independent predictor of progression-free survival and overall survival in patients treated for ovarian carcinoma.

Keywords
Hemoglobin
Ovarian Cancer
Tumor
Neoplasia
Treatment
Share
Back to top